HC Wainwright Reiterates Buy Rating for Nkarta (NASDAQ:NKTX)

Nkarta (NASDAQ:NKTX)‘s stock had its “buy” rating restated by HC Wainwright in a report released on Thursday,Benzinga reports. They currently have a $18.00 price objective on the stock. HC Wainwright also issued estimates for Nkarta’s Q4 2025 earnings at ($0.29) EPS and FY2029 earnings at ($0.99) EPS.

Separately, Needham & Company LLC restated a “buy” rating and issued a $11.00 target price on shares of Nkarta in a research report on Thursday. Six investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Nkarta has a consensus rating of “Buy” and a consensus price target of $14.86.

Nkarta Stock Performance

Nkarta stock opened at $2.00 on Thursday. Nkarta has a one year low of $1.31 and a one year high of $11.84. The company has a 50-day simple moving average of $1.99 and a 200-day simple moving average of $2.87. The firm has a market capitalization of $141.14 million, a P/E ratio of -1.06 and a beta of 0.90.

Nkarta (NASDAQ:NKTX) last posted its earnings results on Wednesday, March 26th. The company reported ($0.35) EPS for the quarter, topping the consensus estimate of ($0.41) by $0.06. As a group, sell-side analysts forecast that Nkarta will post -1.7 earnings per share for the current year.

Insider Buying and Selling

In related news, CEO Paul J. Hastings sold 17,378 shares of Nkarta stock in a transaction dated Wednesday, January 15th. The stock was sold at an average price of $2.20, for a total transaction of $38,231.60. Following the transaction, the chief executive officer now directly owns 319,859 shares of the company’s stock, valued at $703,689.80. The trade was a 5.15 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 8.70% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Nkarta

A number of institutional investors and hedge funds have recently bought and sold shares of NKTX. Wells Fargo & Company MN grew its stake in shares of Nkarta by 27.8% in the 4th quarter. Wells Fargo & Company MN now owns 31,056 shares of the company’s stock worth $77,000 after purchasing an additional 6,763 shares during the last quarter. Catalina Capital Group LLC boosted its holdings in Nkarta by 57.5% during the fourth quarter. Catalina Capital Group LLC now owns 18,818 shares of the company’s stock worth $47,000 after buying an additional 6,867 shares in the last quarter. Price T Rowe Associates Inc. MD grew its position in Nkarta by 41.5% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 23,958 shares of the company’s stock worth $60,000 after buying an additional 7,030 shares during the last quarter. Erste Asset Management GmbH acquired a new stake in shares of Nkarta during the 3rd quarter valued at $33,000. Finally, American Century Companies Inc. boosted its stake in shares of Nkarta by 8.8% during the 4th quarter. American Century Companies Inc. now owns 90,952 shares of the company’s stock worth $226,000 after acquiring an additional 7,378 shares in the last quarter. 80.54% of the stock is owned by institutional investors and hedge funds.

About Nkarta

Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.